Long Ideas - Since our last report on ViroPharma (VPHM), shares of the Exton, Pennsylvania-based company have risen by just under 11%. While positive returns are always welcome, … Continue Reading
Read nowLong Ideas - Despite closing a $26.1M private financing last Wednesday, shares of MethylGene (TSE:MYG) have yet to respond, but precedents suggest that MYG may be in for … Continue Reading
Read nowLong Ideas - Celgene (NASDAQ:CELG) moved closer today to securing another indication for its oncology drug, Abraxane, which is already approved as a second-line treatment for metastatic breast … Continue Reading
Read nowQuick Picks - Spectrum Pharmaceuticals (NASDAQ:SPPI) moves another cancer treatment further along the pipeline on Wednesday with the initiation of a Phase III trial of Zevalin as a … Continue Reading
Read now- Pluristem (NASDAQ:PSTI) continues its upward trend this morning on news Wednesday that the company is partnering with CPC Clinical Research to begin a Phase II … Continue Reading
Read nowInterviews - Discussing Rigel Pharmaceutical’s (NASDAQ:RIGL) immunomodulatory Rheumatoid Arthritis (RA) treatment, CEO Jim Gower says it has the potential to replace TNF inhibitors as the standard-of-care, with … Continue Reading
Read nowResearch - UniQure (QURE) has essentially traded sideways since the company presented the first results from their ongoing open-label study of hemophilia gene therapy AMT-060 in January.
Read now
